Drug cost-effectiveness ... after it was approved in January. ICER has also reiterated its position that the evidence that Leqembi (lecanemab) has a clinical benefit for patients over supportive ...

“ICER’s price recommendations won’t help patients, but they are designed to benefit insurers and pharmacy benefit management firms that fund the group.” Based on a thorough review of ICER ...

CVS last month made waves in pharma with a plan to allow clients to exclude drugs based on guidance from drug cost watchdog ICER ... and plan members, our benefit design will not be discriminatory ...

and says that all provide significant health benefits. However, they are simply too expensive, even after rebates, according to ICER’s calculations. The review covers TNF inhibitors approved for ...